Stuart H. Orkin
Professor
Pediatric Hematologic MalignanciesÂÂ
Dana-Farber Cancer Institute
United States of America
Biography
Dr. Orkin received his MD in 1972 from Harvard Medical School, followed by postdoctoral research at the National Institutes of Health and clinical training in pediatrics and hematology-oncology at Children's Hospital Boston and DFCI, where he joined the faculty in 1978. Dr. Orkin is a Howard Hughes Medical Institute Investigator. Over the past decade, his laboratory has defined critical nuclear regulators of hematopoiesis.
Research Interest
Pediatric hematology/oncology
Publications
-
Nguyen M, Li S, Bradner JE, Orkin SH et al (2016) Chronic Myelogenous Leukemia- Initiating Cells Require Polycomb Group Protein EZH2. Cancer Discov 11 :1237-1247.
-
Canver MC, Bauer DE, Orkin SH (2017) Functional interrogation of non-coding DNA through CRISPR genome editing. Methods 122 :118-129.
-
Kim W, Novina CD, Hahn WC, Marto JA, Orkin SH et al (2017) PRMT1-Mediated Translation Regulation Is a Crucial Vulnerability of Cancer. Cancer Res.
